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Background: Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, is used to treat solid tumors and
tuberous sclerosis complex (TSC). Stomatitis, an inflammation of the mucous membranes of the mouth, is a common
adverse event associated with mTOR inhibitors, including everolimus. We conducted a meta-analysis of data from
seven randomized, double-blind phase 3 clinical trials of everolimus to determine the clinical impact of stomatitis on
efficacy and safety.
Patients and methods: Data were pooled from the safety sets of solid tumor [breast cancer (BOLERO-2 and BOLERO-
3), renal cell carcinoma (RECORD-1), carcinoid tumors (RADIANT-2), and pancreatic neuroendocrine tumors (RADIANT-
3)] and TSC studies (EXIST-1 and EXIST-2). Data from solid tumor trials and TSC trials were analyzed separately.
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Results: The rate of stomatitis was 67% in the solid tumor trials (973/1455 patients) and 70% in the TSC trials (110/157
patients). Most stomatitis events were grade 1/2, with grade 3/4 events reported in only 9% (solid tumor trials) and 8%
(TSC trials) of patients. Low TSC patient numbers prevented an in-depth evaluation of stomatitis and response. In the solid
tumor trials, most first stomatitis episodes (89%; n = 870) were observed within 8 weeks of starting everolimus. Patients
with stomatitis occurring within 8 weeks of everolimus initiation had longer progression-free survival (PFS) than everolimus-
treated patients without stomatitis in BOLERO-2 {8.5 versus 6.9 months, respectively; hazard ratio (HR), 0.78 [95% confi-
dence interval (CI), 0.62–1.00]} and RADIANT-3 [13.9 versus 8.3 months, respectively; HR, 0.70 (95% CI, 0.48–1.04)]. A
similar trend was observed in RECORD-1 [HR, 0.90 (95% CI, 0.66–1.22)] and RADIANT-2 [HR, 0.87 (95% CI, 0.61–1.22)]
but not in BOLERO-3 [HR, 1.01 (95% CI, 0.75–1.36)].
Conclusions: Stomatitis did not adversely affect PFS, supporting the administration of everolimus in accordance with
standard management guidelines.
Key words: everolimus, stomatitis, breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumors, tuberous
sclerosis complex
introduction
Everolimus is an oral mammalian target of rapamycin (mTOR)
inhibitor that is commonly used in the treatment of cancer
[renal cell carcinoma (RCC), pancreatic neuroendocrine tumors
(pNET), and hormone receptor-positive (HR+)/human epider-
mal growth factor receptor 2-negative (HER2−) breast cancer]
as well as tuberous sclerosis complex (TSC) [1]. One of the most
common adverse events (AEs) associated with mTOR inhibitors
is stomatitis, an inflammation of the mucous membranes of
the mouth [1, 2]. In particular, mTOR inhibitor-associated
stomatitis is similar to aphthous ulceration, characterized
by small, distinct ovoid ulcers that are gray and surrounded by
an erythematous ring, and which affect the non-keratinized
mucosa of the oral cavity. Stomatitis is clinically distinct from
mucositis, which is associated with conventional chemotherapy
or ionizing radiation and generally presents as non-uniform
erythematous and ulcerated lesions that may extend to the
gastrointestinal tract [3].
The clinical impact of stomatitis on efficacy is of particular
interest, and greater understanding of this AE may help physicians
anticipate and manage this event. Therefore, we conducted a
meta-analysis of individual patient data from seven randomized,
double-blind phase 3 clinical trials of everolimus in patients with
advanced breast cancer, pNET, and RCC as well as in patients
with TSC [4–10]. Here, we report on the incidence, time to
occurrence, and severity of stomatitis and assess the impact on
clinical outcome. Our results show that stomatitis did not adverse-
ly affect progression-free survival (PFS) and support the adminis-
tration of everolimus in accordance with standard management
guidelines.
methods
studies
Data were pooled from the safety sets (patients who received ≥1 dose of
study drug) of seven randomized, double-blind phase 3 clinical trials of ever-
olimus conducted in patients with advanced solid tumors and TSC
(Table 1). Due to inconsistencies regarding the precise terms used to report
AEs in clinical trials, a broad inclusive definition was applied to capture sto-
matitis events that may not have been recorded as such. The meta-analysis
included patients with AEs of aphthous stomatitis, gingival swelling, gingival
pain, gingival ulceration, glossitis, glossodynia, lip ulceration, mouth ulcer-
ation, mucosal inflammation, mucosal ulceration, stomatitis, or tongue ul-
ceration, per the preferred terms of the Medical Dictionary for Regulatory
Activities version 16.0. Events were included in the analysis if they occurred
during the double-blind treatment period or up to 28 days after the last dose
of study drug.
Stomatitis was characterized and graded per Clinical Trials Criteria for
Adverse Events v3.0, and defined as follows: minimal symptoms with
normal diet, not requiring medical intervention (grade 1); symptomatic, can
eat and drink a modified diet, respiratory symptoms requiring medical inter-
vention but not interfering with activities of daily living (grade 2); symptom-
atic, affecting ability to eat and drink adequately, respiratory symptoms
affecting activities of daily living (grade 3); symptoms with life-threatening
consequences (grade 4).
analyses
Solid tumor trial data were analyzed separately from TSC trial data. Time to
first occurrence of stomatitis was defined as the time from the start of study
treatment to the date of the first occurrence of stomatitis. In the absence of
stomatitis, patients were censored if they died, received new anticancer
therapy, discontinued double-blind study treatment, or were still receiving
treatment at the cutoff date. Recurrent stomatitis was defined as a second sto-
matitis event starting ≥2 days after resolution of the first event. Time to re-
current stomatitis was defined as the date of the start of recurrence minus
the date of first occurrence resolution. The Kaplan–Meier methods were
used to analyze time to the first episode of stomatitis and time from the end
of the first episode to the second episode of stomatitis.
The association between stomatitis and PFS was evaluated by comparing
investigator-assessed PFS between patients with and without stomatitis
within 8 weeks (i.e. 56 days) of the start of everolimus. The 8-week interval
was selected to be long enough to include most first stomatitis episodes
(89%; n = 870) and as it constitutes an easy-to-understand time interval
(8 weeks = 2 months). Stratified Cox regression analyses used stratification
factors as defined in individual study protocols and were adjusted for add-
itional known baseline prognostic factors, including Eastern Cooperative
Oncology Group performance status of 0 versus 1–2 at baseline and Asian
versus non-Asian for BOLERO-2; Asian versus non-Asian for RADIANT-3
and BOLERO-3; Karnofsky performance status of ≤80 versus >80 for
RECORD-1; and age <65 versus ≥65 years, Caucasian yes versus no, World
Health Organization performance status of 0 versus 1 or 2, and lung
origin yes versus no for RADIANT-2. Hazard ratios (HRs) were corrected
for the confounding effect of duration of exposure using a bootstrap-based
method.
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results
solid tumor trials
incidence and risk. A total of 1455 patients treated with
everolimus in the solid tumor trials were included in the
analysis (Table 1). Of these, 973 patients (67%) experienced
stomatitis, with most of all first episodes (89%; n = 870) occurring
within 8 weeks of the start of everolimus. The incidence of
stomatitis ranged from 59% in RECORD-1 to 71% in BOLERO-3.
By comparison, the incidence in the 1071 patients in the control
arms was 19% [range, 11% in RECORD-1 (placebo) to 29% in
BOLERO-3 (placebo + trastuzumab + vinorelbine)]. Of the 973
patients treated with everolimus who experienced an initial
stomatitis event, 388 (40%) experienced a second episode.
The Kaplan–Meier plots and exploratory Cox models strati-
fied by study were used to assess the influence of body mass
index (BMI), age, and history of diabetes on time to the first sto-
matitis event. Stomatitis rates tended to be lower in patients
with BMI > 25 kg/m2 than in patients with BMI ≤ 25 kg/m2
(64% and 70%, respectively). Additionally, the median time
to the first stomatitis event was longer for patients with
BMI > 25 kg/m2 than in those with BMI≤ 25 kg/m2 (29 and
20 days, respectively), with an estimated HR of 0.83 [95% confi-
dence interval (CI), 0.73–0.94; supplementary Figure S1A, avail-
able at Annals of Oncology online]. These results may be related
to exposure. Patients ≥65 years of age had a slightly lower inci-
dence of stomatitis than patients <65 years of age (64% and
68%, respectively) and a slightly longer median time to the first
stomatitis event [29 and 22 days, respectively; HR, 0.90 (95% CI,
0.78–1.03); supplementary Figure S1B, available at Annals of
Oncology online]. However, this may be confounded by an indi-
cation effect since BOLERO-3, which had the lowest median
age, had the highest rate of stomatitis. Additionally, we noted
that patients with no prior history of diabetes had an apparently
higher rate of stomatitis than patients with prior diabetes (68%
and 59%, respectively) and a shorter median time to the first
stomatitis event [23 and 54 days, respectively; HR, 1.27 (95% CI,
1.04–1.55); supplementary Figure S1C, available at Annals of
Oncology online]; this result could also be confounded by indi-
cation (breast cancer trials had fewer patients with a history of
diabetes and higher rates of stomatitis) or other factors.
grade and study treatment impact. Although the overall incidence
of stomatitis of any grade in the everolimus-containing arms
was 67%, most stomatitis events were grade 1/2, with grade
3/4 events reported in 9% of patients and only 1 patient
experiencing grade 4 stomatitis (0.1%). Among the 388 patients
who experienced at least two stomatitis events, the rate of grade
3/4 episodes was lower at the time of recurrence (7.2% versus
12.1% for the initial episode; Figure 1).
Stomatitis led to dose reductions and/or interruptions in 236
of 973 patients (24%) during episode 1 and 88 of 388 patients
(23%) during episode 2. During the first stomatitis episode, dose
reductions and/or interruptions were more frequent in patients
enrolled in breast cancer trials (32% in BOLERO-2 and 34% in
BOLERO-3 versus 12%–17% in the non-breast cancer studies),
in which everolimus was administered in combination with other
agents. Dose reductions were also more frequent in patients who
experienced grade 3/4 stomatitis (87% versus 17% for grade 1/2).
Discontinuation due to stomatitis was reported in 2% of patients
(25 of the 1455 everolimus-treated patients), after the first
(n = 14), second (n = 9), third (n = 1), or fifth (n = 1) episode.
analyses of time to stomatitis event. Based on the Kaplan–
Meier estimates, the rate of any-grade stomatitis was 60.8%
(95% CI, 58.3%–63.3%) at 2 months, and the median time to
Table 1. Phase 3 clinical studies included in the meta-analysis
Study Patient population Treatment arms na
Solid tumor studies
BOLERO-2 [4] HR+/HER2− advanced breast cancer Everolimus (10 mg/day) + exemestane 482
Placebo + exemestane 238
BOLERO-3 [5] HER2+ advanced breast cancer Everolimus (5 mg/day) + trastuzumab + vinorelbine 280
Placebo + trastuzumab + vinorelbine 282
RADIANT-2 [6] Advanced carcinoid tumor Everolimus (10 mg/day) + octreotide LAR 215
Placebo + octreotide LAR 211
RADIANT-3 [7] Advanced pNET Everolimus (10 mg/day) 204
Placebo 203
RECORD-1 [8] Advanced RCC Everolimus (10 mg/day) 274
Placebo 137
TSC studies
EXIST-1 [9] TSC (SEGA) Everolimus (titrated to blood trough concentration of 5 to 15 ng/ml) 78
Placebo 39
EXIST-2 [10] TSC (renal angiomyolipoma) Everolimus (10 mg/day) 79
Placebo 39
HER2−, human epidermal growth factor receptor 2-negative; HER2+, human epidermal growth factor receptor 2-positive; HR+, hormone receptor-
positive; LAR, long-acting repeatable; pNET, pancreatic neuroendocrine tumors; RCC, renal cell carcinoma; SEGA, subependymal giant cell astrocytoma;
TSC, tuberous sclerosis complex.
aNumber of patients in the safety set.
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the first episode was 0.8 months (95% CI, 0.7–1.0 months;
Figure 2A). Among patients who experienced ≥1 stomatitis
event (any grade), time to recurrence was longer than time to
first occurrence, with a 2-month Kaplan–Meier estimate of
28.0%. The apparent time to recurrence was slightly shorter
after grade 3/4 events (supplementary Figure S2, available at
Annals of Oncology online).
impact on PFS. Compared with patients in the control arms
in the solid tumor studies, PFS was longer in patients treated
with everolimus, regardless of whether they experienced a
stomatitis event within the first 8 weeks of treatment (Figure 3).
Interestingly, in the BOLERO-2 breast cancer and RADIANT-3
advanced pNET trials, the occurrence of stomatitis within
8 weeks of everolimus initiation was associated with longer PFS
than the absence of stomatitis in everolimus-treated patients.
Specifically, in BOLERO-2, the median PFS was 8.5 versus
6.9 months for everolimus-treated patients with versus without
stomatitis within 8 weeks, respectively [HR, 0.78 (95% CI, 0.62–
1.00)]. In RADIANT-3, the median PFS was 13.9 versus
8.3 months for everolimus-treated patients with versus without
stomatitis within 8 weeks, respectively [HR, 0.70 (95% CI, 0.48–
1.04)]. A similar trend was observed in RECORD-1 [HR, 0.90
(95% CI, 0.66–1.22)] and RADIANT-2 [HR, 0.87 (95% CI,
0.61–1.22)] but not in BOLERO-3 [HR, 1.01 (95% CI, 0.75–
1.36)]. A relationship between grade of stomatitis and efficacy
was not seen; however, the relatively small number of grade 3/4
stomatitis events limits the interpretation of these data (data not
shown).
TSC trials
Across the two TSC trials (EXIST-1 and EXIST-2), 110 of the
157 patients (70%) treated with everolimus reported stomatitis
of any grade, including 12 patients (8%) with a grade 3/4 event.
Stomatitis led to dose adjustment/interruption in 10 patients
(6%) and was not reported to have led to study drug discontinu-
ation in any patients. Based on the Kaplan–Meier estimates,
the rate of any-grade stomatitis was 61.3% at 2 months, and the
median time to the first episode was 1 month (Figure 2B). Due
to the small number of patients in the TSC population, we were
unable to evaluate the relationship between stomatitis and
response.
discussion
Stomatitis is a common complication of mTOR inhibitor treat-
ment. In our meta-analysis of phase 3 studies, we used a broad
definition to capture stomatitis events not specifically categor-
ized as such, and found that the overall rate (any grade) of the
AE was similar across studies of four different advanced solid
tumors (67%) and across the TSC trials (70%). We also noted
that the incidence of grade 3/4 events was low (9% in solid
tumor trials and 6% in TSC trials). Among patients who experi-
enced two events (n = 388), the severity of the second event
appeared to be lower than that of the first (grade 3/4 event rates
of 7% and 12%, respectively), which could reflect the use of
prophylactic measures and/or dose reduction. Indeed, dose
reductions and/or interruptions due to stomatitis were more fre-
quent in patients with grade 3/4 events and in patients enrolled
in clinical trials of breast cancer. We noted, however, that drug
discontinuation due to stomatitis was rare (2%). These results
should be interpreted with caution, as they do not account for
shorter duration of everolimus exposure in patients discontinu-
ing due to disease progression or the use of reduced everolimus
doses following a first event. Other factors, including dose (10
versus 5 mg/day) and treatment regimen (single versus multiple
agent), may impact these results.
The onset of stomatitis was rapid (median, ≤1 month). At
2 months, the rate of stomatitis (any grade) was 60.8% in solid
tumor trials and 61.3% in TSC trials. These data support the im-
portance of early follow-up and awareness of AE management
guidance in the approved prescribing information.
Of particular interest, the benefit of everolimus in patients
who experienced stomatitis was consistent with that observed in
the overall population. Additionally, stomatitis was associated
with longer PFS in the BOLERO-2 and RADIANT-3 studies.
A similar trend was reported in RECORD-1 and RADIANT-2
A B C 
Grade 3, 10.3%  
Grade 4, 0.1%  
Grade 1, 53.9%
Grade 2, 35.8%
Grade 3, 12.1%
Grade 4, 0.0%
Grade 3, 7.2%
Grade 4, 0.0%
Grade 1, 42.0%
Grade 2, 45.9%  
Grade 1, 60.8%
Grade 2, 32.0%  
Figure 1. Grade of first and second stomatitis episodes in solid tumor trials. (A) First episode in patients with ≥1 stomatitis event (n = 973); (B) first episode
in patients with ≥2 stomatitis events (n = 388); (C) second episode in patients with ≥2 stomatitis events (n = 388). Data shown are crude rates that do not
account for study discontinuation.
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but not in BOLERO-3, which limits broader interpretation. The
reason for the differences in findings between trials is unknown
but may be due to differences in drug exposure and/or in-
teraction with combination therapies. Moreover, the findings
should be interpreted with caution due to the retrospective/
exploratory nature of the analyses. Also, due to the small
number of patients with TSC, an in-depth evaluation of the rela-
tionship between stomatitis and response was not possible in
this population.
There was some evidence that patients with higher BMI
(>25 kg/m2) had slightly lower rates of stomatitis and longer onset
to first occurrence than patients with lower BMI (≤25 kg/m2),
which may be related to lower exposure to everolimus in patients
with higher BMI. The observed effects of age and history of dia-
betes on stomatitis rates and time to first stomatitis event may
have been confounded by study indication or other factors and
should be interpreted with caution.
conclusion
Overall, the results of this meta-analysis suggest that stomatitis
did not adversely affect PFS. The findings suggest that with early
follow-up (within 2 weeks), proactive management, and dose
adjustments according to approved prescribing information in
patients who experience stomatitis, everolimus can be adminis-
tered with confidence regarding patient comfort, compliance,
and safety. Indeed, in a study of patients with HR+ advanced
breast cancer treated with everolimus and exemestane in
German centers, 87% of patients received prophylactic stoma-
titis treatment. The reported rate of stomatitis (any grade) was
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Figure 2. Time to first stomatitis event. The Kaplan–Meier estimates of time to the first stomatitis event in everolimus-treated patients in (A) solid tumor and
(B) TSC trials. Symbols represent censoring times.
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Figure 3. Association of stomatitis with PFS. The Kaplan–Meier estimates of PFS are shown for patients in the everolimus arms (with versus without stoma-
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free survival; wk, weeks.
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40%—less than the 59% reported in the BOLERO-2 trial
using the same regimen [4, 11]. Ongoing prospective studies
(NCT02376985, NCT02229136, NCT02015559, NCT02069093,
and NCT02273752) will determine the value of dental/oral
hygiene measures, mucoadhesive oral wound rinses, pharmaco-
kinetic-based dose adjustments, and prophylactic steroid-based
mouthwash in reducing the incidence of everolimus-induced
stomatitis and improving its management [12].
acknowledgements
Financial support for medical editorial assistance was provided
by Novartis Pharmaceuticals Corporation. We thank Peter
J. Simon, PhD, for medical editorial assistance with this
manuscript.
funding
This work was supported by Novartis Pharmaceuticals
Corporation. No grant number is applicable.
disclosure
HSR discloses funding for research support paid to the Regents
of UC from Novartis Pharmaceuticals Corporation, Pfizer, Lily,
Genentech, Macrogenics, Merck, Celsion, OBI, Clovis, Insight
and Biomarin; honoraria from Genomic Heath. GNH discloses
grant support and personal fees for membership on the trial
Steering Committee from Novartis Pharmaceuticals Corporation;
personal fees from Bayer HealthCare Pharmaceuticals, MetaStat,
Novartis Pharmaceuticals Corporation, Pfizer, Antigen Express,
Galena Biopharma, Amgen, and Rockpointe for membership
on scientific/advisory committees; personal fees from Peregrine
Pharmaceuticals, Celgene, and Genentech for consulting; person-
al fees from the Society for Translational Oncology and
AstraZeneca Pharmaceuticals for speaker/preceptorship; mem-
bership on the Scientific/Advisory Committee for Oncimmune.
JY discloses personal fees from Novartis Pharmaceuticals
Corporation for consultancy and grants. MP discloses personal
fees from Novartis Pharmaceuticals Corporation for membership
on the advisory board and presentations. AR discloses grant
support, personal fees, and non-financial support from Novartis
Pharmaceuticals Corporation. DF discloses consulting fees (paid
to employer), and travel expenses and personal fees from
Novartis Pharmaceuticals Corporation. FR, JG, NR, and OA dis-
close employment with Novartis Pharma AG. RM discloses per-
sonal fees from Pfizer and Novartis Pharmaceuticals Corporation
for consulting; grant support from Novartis Pharmaceuticals
Corporation for clinical trial support.
references
1. Boers-Doets CB, Raber-Durlacher JE, Treister NS et al. Mammalian target of
rapamycin inhibitor-associated stomatitis. Future Oncol 2013; 9: 1883–1892.
2. Martins F, de Oliveira MA, Wang Q et al. A review of oral toxicity associated with
mTOR inhibitor therapy in cancer patients. Oral Oncol 2013; 49: 293–298.
3. Sonis ST, Elting LS, Keefe D et al. Perspectives on cancer therapy-induced
mucosal injury: pathogenesis, measurement, epidemiology, and consequences for
patients. Cancer 2004; 100: 1995–2025.
4. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-
receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520–529.
5. Andre F, O’Regan R, Ozguroglu M et al. Everolimus for women with trastuzumab-
resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised,
double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 580–591.
6. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting
repeatable for the treatment of advanced neuroendocrine tumours associated with
carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3
study. Lancet 2011; 378: 2005–2012.
7. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine
tumors. N Engl J Med 2011; 364: 514–523.
8. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal
cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116:
4256–4265.
9. Franz DN, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for
subependymal giant cell astrocytomas associated with tuberous sclerosis complex
(EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet
2013; 381: 125–132.
10. Bissler JJ, Kingswood JC, Radzikowska E et al. Everolimus for angiomyolipoma
associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
(EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet 2013; 381: 817–824.
11. Fasching PA, Decker T, Schneeweiss A et al. Breast cancer treatment
with everolimus and exemestane for ER+ women - results of the 2nd
interim analysis of the non-interventional trial BRAWO. Ann Oncol 2014; 25:
abstr LBA9.
12. Rugo HS, Chambers MS, Litton JK et al. Prevention of stomatitis in patients with
hormone receptor-positive advanced breast cancer treated with everolimus plus
exemestane: a phase II study of a steroid-based mouthwash. J Clin Oncol 2014;
32: TPS661.
Volume 27 | No. 3 | March 2016 doi:10.1093/annonc/mdv595 | 
Annals of Oncology original articles
